Table 3.
Multivariate analyses of overall survival
| Covariate | Adjusted hazard ratioa | 95% CI | P-valueb |
|---|---|---|---|
| Model for RTOG 0020 CXRT and 98-12 | |||
| Treatment (0 = 98-12, 1 = 0020 CXRT) | 1.13 | (0.85, 1.51) | 0.15c |
| Treatment stage (0 = T1–2, Tx, 1 = T3–4) | 1.64 | (1.09, 2.46) | 0.02 |
| Model for RTOG 0020 CXRT+R115777 and 98-12 | |||
| Treatment (0 = 98-12, 1 = 0020 CXRT+R115777) | 1.54 | (1.16, 2.06) | >0.99c |
Notes:
a
Hazard ratio: an HR > 1 indicates an increased risk for the second level of the variable;
b
P-value from Cox proportional hazards model;
c
one-sided test per statistical design, testing RTOG 0020 better than RTOG 98-12.
Abbreviations: CI, confidence interval; CXRT, concurrent radiation with gemcitabine and paclitaxel; R115777, farnesyl transferase inhibitor; RTOG 0020 and 98-12, Radiation Therapy Oncology Group studies 0020 and 98-12.